QURE Oct 2024 6.000 call
| Previous close | 0.7000 |
| Open | 0.6100 |
| Bid | 0.0000 |
| Ask | 0.8500 |
| Strike | 6.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.6000 - 0.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 30 |
Simply Wall St.uniQure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
uniQure ( NASDAQ:QURE ) First Quarter 2024 Results Key Financial Results Revenue: US$8.49m (up 59% from 1Q 2023). Net...
GlobeNewswireuniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in third quarter of 2024 ~ ~ Comprehensive review of operations and options to reduce expenses underway and expected to be completed in mid-2024 ~ LEXINGTON, Mass. and AMSTERDAM, May 07, 20
Insider Monkey13 Best Biotech Stocks To Buy Under $20
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]
